These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 19009920)
1. Impact of routine immunization using meningococcal C conjugate vaccine on invasive meningococcal disease in British Columbia. Siu T; Tang W; Dawar M; Patrick DM Can J Public Health; 2008; 99(5):380-2. PubMed ID: 19009920 [TBL] [Abstract][Full Text] [Related]
2. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment. Wormsbecker AE; Wong K; Jamieson FB; Crowcroft NS; Deeks SL Vaccine; 2015 Oct; 33(42):5678-5683. PubMed ID: 26299749 [TBL] [Abstract][Full Text] [Related]
3. Reduction in Neisseria meningitidis infection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994-2012 series. de Waure C; Miglietta A; Nedovic D; Mereu G; Ricciardi W Hum Vaccin Immunother; 2016; 12(2):467-73. PubMed ID: 26308192 [TBL] [Abstract][Full Text] [Related]
4. Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study. Ohm M; Hahné SJM; van der Ende A; Sanders EAM; Berbers GAM; Ruijs WLM; van Sorge NM; de Melker HE; Knol MJ Clin Infect Dis; 2022 Jul; 74(12):2173-2180. PubMed ID: 34525199 [TBL] [Abstract][Full Text] [Related]
5. Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile. Villena R; Valenzuela MT; Bastías M; Santolaya ME Vaccine; 2019 Oct; 37(46):6915-6921. PubMed ID: 31585728 [TBL] [Abstract][Full Text] [Related]
6. Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction. Villena R; Valenzuela MT; Bastías M; Santolaya ME Vaccine; 2022 Jan; 40(4):666-672. PubMed ID: 34996641 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model. Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896 [TBL] [Abstract][Full Text] [Related]
8. [Invasive meningococcal disease in the Czech Republic - analysis of the epidemiological situation and vaccination strategy recommendations]. Křížová P; Vacková Z; Musílek M; Kozáková J Epidemiol Mikrobiol Imunol; 2013 Dec; 62(4):138-47. PubMed ID: 24467175 [TBL] [Abstract][Full Text] [Related]
9. Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil. Evellyn do Macedo L; Ferreira VM; Feitosa CA; Nunes AMPB; Campos LC; Sáfadi MAP Hum Vaccin Immunother; 2018 May; 14(5):1131-1137. PubMed ID: 29236585 [TBL] [Abstract][Full Text] [Related]
10. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014. Whittaker R; Dias JG; Ramliden M; Ködmön C; Economopoulou A; Beer N; Pastore Celentano L; Vaccine; 2017 Apr; 35(16):2034-2041. PubMed ID: 28314560 [TBL] [Abstract][Full Text] [Related]
11. Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada. De Wals P; Deceuninck G; Lefebvre B; Tsang R; Law D; De Serres G; Gilca V; Gilca R; Boulianne N Clin Infect Dis; 2017 May; 64(9):1263-1267. PubMed ID: 28207068 [TBL] [Abstract][Full Text] [Related]
12. Current Epidemiology and Trends in Meningococcal Disease-United States, 1996-2015. MacNeil JR; Blain AE; Wang X; Cohn AC Clin Infect Dis; 2018 Apr; 66(8):1276-1281. PubMed ID: 29126310 [TBL] [Abstract][Full Text] [Related]
13. Surveillance of invasive meningococcal disease in the south of Brazil: considerations of immunization programme. Silveira MM; Crespo da Silva PA; Conrad NL; Oliveira TL; Hartwig DD; Trotter C J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33544069 [TBL] [Abstract][Full Text] [Related]
14. Meningococcal disease epidemiology in Australia 10 years after implementation of a national conjugate meningococcal C immunization programme. Lawrence GL; Wang H; Lahra M; Booy R; McINTYRE PB Epidemiol Infect; 2016 Aug; 144(11):2382-91. PubMed ID: 27094814 [TBL] [Abstract][Full Text] [Related]
15. Analysis of meningococcal vaccine uptake in patients with invasive meningococcal disease, Czech Republic, 2006-2022. Křížová P; Okonji Z; Honskus M Epidemiol Mikrobiol Imunol; 2023; 72(4):243-247. PubMed ID: 38242709 [TBL] [Abstract][Full Text] [Related]
16. Surveillance of invasive meningococcal disease in southern Brazil: considerations of an immunization programme. Silveira MM; Crespo da Silva PA; Conrad NL; Oliveira TL; Hartwig DD; Trotter C J Med Microbiol; 2023 Feb; 72(2):. PubMed ID: 36753430 [TBL] [Abstract][Full Text] [Related]
17. Meningococcal disease before and after the introduction of meningococcal serogroup C conjugate vaccine. Federal District, Brazil. Tauil Mde C; Carvalho CS; Vieira AC; Waldman EA Braz J Infect Dis; 2014; 18(4):379-86. PubMed ID: 24698710 [TBL] [Abstract][Full Text] [Related]
18. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification. Garrido-Estepa M; León-Gómez I; Herruzo R; Cano R Vaccine; 2014 May; 32(22):2604-9. PubMed ID: 24662700 [TBL] [Abstract][Full Text] [Related]
19. Need for Optimisation of Immunisation Strategies Targeting Invasive Meningococcal Disease in the Netherlands. Bousema JC; Ruitenberg J Int J Health Policy Manag; 2015 Sep; 4(11):757-61. PubMed ID: 26673336 [TBL] [Abstract][Full Text] [Related]
20. Epidemiological and Molecular Characterization of Invasive Meningococcal Disease in Italy, 2008/09-2012/13. Neri A; Pezzotti P; Fazio C; Vacca P; D'Ancona FP; Caporali MG; Stefanelli P PLoS One; 2015; 10(10):e0139376. PubMed ID: 26445461 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]